Eupraxia Pharmaceuticals
Cash Flow
Last updated:
Cash flow statement presents a set of outflows and inflows of cash within a company through operating, investing and financing activities. Over the last year, operating activities of Eupraxia Pharmaceuticals generated cash of -$27,916,416, which is less than the previous year. Cash used in financing activities reached the amount of $27,842,879 last year. Net change in cash is therefore $1,078,367.
Cash Flow
| 2017 | -5.29M | -314.68K | 9.46M |
|---|---|---|---|
| 2018 | -8.32M | -141.85K | 5.29M |
| 2019 | -5.17M | -1.89M | 7.39M |
| 2020 | -403.92K | 24.61K | -626.64K |
| 2021 | -14.64M | -14.44M | 49.91M |
| 2022 | -18.77M | 8.70M | 13.52M |
| 2023 | -27.91M | -99.03K | 27.84M |
EPRX.TO Cash Flow Statement (2017 – 2023)
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|
Cash at beginning of period | 18.26M | 20.89M | 150.12K | 1.15M | 823.48K | 3.99M | 136.09K |
Operating activities | |||||||
Net income | -37.39M | -23.91M | -23.36M | -4.01M | -7.24M | -14.83M | -4.99M |
| Adjustments to reconcile net income to cash generated by operating activities: | |||||||
Depreciation and amortization | 209.91K | 193.27K | 111.52K | 116.80K | 201.93K | 125.82K | 85.37K |
Stock-based compensation expense | 1.41M | 1.43M | 4.21M | 228.68K | 544.95K | 0 | 162.82K |
| Deferred income tax benefit | 1.41M | 1.43M | 4.21M | 228.68K | 544.95K | 0 | 162.82K |
| Changes in operating assets and liabilities: | |||||||
Accounts receivable, net | -139.97K | 310.06K | 190.88K | 727.68K | 135.27K | -208.57K | -340.21K |
Inventories | -577.90K | -1.32M | 0 | 0 | 0 | 0 | 0 |
Accounts payable | 577.90K | 1.32M | 0 | 0 | 0 | 0 | 0 |
Cash generated by operating activities | -27.91M | -18.77M | -14.64M | -403.92K | -5.17M | -8.32M | -5.29M |
Investing activities | |||||||
Purchases Of Investments | 0 | -310 | -9M | 0 | 0 | 0 | 0 |
Investments In Property Plant And Equipment | -97.22K | -308.37K | -431.67K | 0 | -9.47K | -141.85K | -314.68K |
Acquisitions Net | 0 | 310 | 0 | 81.30K | 0 | 0 | 0 |
Cash generated by investing activities | -99.03K | 8.70M | -14.44M | 24.61K | -1.89M | -141.85K | -314.68K |
Financing activities | |||||||
Common Stock Issued | 15.88M | 10.63M | 37.83M | 0 | 0 | 0 | 7.19M |
Payments for dividends | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repurchases of common stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Repayments of term debt | -144.43K | -97.48K | -586.42K | -1.10M | 5.66M | -7.34K | 463.06K |
Cash used in financing activities | 27.84M | 13.52M | 49.91M | -626.64K | 7.39M | 5.29M | 9.46M |
Net Change In Cash | 1.07M | 3.84M | 20.74M | -1.00M | 332.59K | -3.16M | 3.85M |
Cash at end of period | 19.34M | 24.73M | 20.89M | 150.12K | 1.15M | 823.48K | 3.99M |
| Data source | Data source | Data source | Data source | Data source | Data source | Data source |